Home
Clinical Resources Search
PQI: PARP Inhibitor Eligibility in Ovarian Cancer

PARP Inhibitor Eligibility in Ovarian Cancer

Download PQI pdf 0.15MB

Last Updated: September 6, 2023

By: Martina Fraga, PharmD

About this PQI

The purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Ovarian Lynparza Neratinib Olaparib Rubraca Rucaparib Talazoparib Talzenna Zejula

PQI

Frequently Searched

Supported by

PARP Inhibitor Eligibility in Ovarian Cancer

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Zolbetuximab (Vyloy®) for Gastroesophageal Cancers

PQI: Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

PQI: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI: Ibrutinib Dosing Optimization

PQI in Action: Larotrectinib (Vitrakvi®) Overview

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

S8 Bonus Eps 2: Inside ASCO 2025

S8 E15: Supporting Survivors at Work

S8 E14: Advancing Geriatric Oncology

S8 Ep 13: Supporting Patients Through Financial Assistance

Readiness Tracker

Treatment Support Kit: Mirdamentinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

PQI: Neratinib (Nerlynx®) Diarrhea Management

Treatment Support Kit: Neratinib

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer

PQI: Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

PQI: Olaparib (Lynparza®) Clinical Management

PQI: Olaparib (Lynparza®) Adverse Event Management

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

PQI: Use of Rucaparib (Rubraca®) and Indications

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Talazoparib (Talzenna®) and Enzalutamide (Xtandi®) in HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

PQI: Niraparib (Zejula®): Dose Modifications Based on Weight and Platelet Counts

PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices

Medically Integrated Oncology Treatment Discussion Guide

S8 Bonus Eps 2: Inside ASCO 2025

Treatment Support Kit: Mirdamentinib

S8 E15: Supporting Survivors at Work